# Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers

> **NCT07304726** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 30 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** CKD-383 0.25/12.5/1000mg
- **DRUG:** CKD-501, D745, D150

## Key facts

- **NCT ID:** NCT07304726
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-30
- **Primary completion:** 2025-11-09
- **Final completion:** 2025-11-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07304726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07304726, "Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07304726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*